Skip to main content
. 2019 Feb 7;20(3):714. doi: 10.3390/ijms20030714

Figure 2.

Figure 2

Systemic AN7 treatment reduces choroidal neovascularization (CNV) area. (A) Representative images of choroidal flatmounts from day 7 post laser application, with CNV lesions sites from mice treated with saline, AN7 or bevacizumab. Fluorescein isothiocyanate dextran (FITC-dextran) (green) perfused through the blood vessels of the eyes and is seen at the laser lesion site, indicative of CNV formation. Scale bar, 100 µm. (B) Quantification of FITC area in choroidal flatmounts (indicative of CNV area) on day 7 from laser photocoagulation. Three laser applications were performed on the right eyes and mice were randomized to intraperitoneal (IP) 20 mg/kg AN7 or 10 mg/kg AN7 or IP saline-control groups, administered immediately following laser photocoagulation and for a total of three times a week thereafter. One-way ANOVA followed by Sidak post hoc test was used for statistical analysis. n = number of eyes per group. (C) Quantification of FITC area in choroidal flatmounts (indicative of CNV area) on day 7 post laser photocoagulation. Three laser applications were performed on the right eyes. IP injections of AN7 were compared to intravitreal (IVT) injection of bevacizumab and to corresponding saline controls. IP injections of AN7 or saline were administered immediately following laser applications and for a total of three times a week thereafter. IVT injections of bevacizumab or saline were administered once, immediately following the laser applications. One-way ANOVA followed by Sidak post-hoc test was used for statistical analysis. n = number of eyes per group.